AHSA1 Regulates Hepatocellular Carcinoma Progression via the TGF-β/Akt-Cyclin D1/CDK6 Pathway

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(11):1295–1307. doi:10.1080/17474124.2021.1991792
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi:10.1002/ijc.33588
   Web of Science ®Google Scholar
• Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: outcomes and future horizons. World J Gastroenterol. 2021;27(43):7462–7479. doi:10.3748/wjg.v27.i43.7462
   PubMed Web of Science ®Google Scholar
• Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: current evidence and future directions. World J Gastroenterol. 2019;25(32):4614–4628. doi:10.3748/wjg.v25.i32.4614
   PubMed Web of Science ®Google Scholar
• Terashima T, Yamashita T, Takata N, et al. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 2020;50(7):871–884. doi:10.1111/hepr.13505
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Scartozzi M, Tada T, et al. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int. 2021;41(6):1389–1397. doi:10.1111/liv.14817
   PubMed Web of Science ®Google Scholar
• Fulgenzi CAM, Talbot T, Murray SM, et al. Immunotherapy in Hepatocellular carcinoma. Curr Treat Options Oncol. 2021;22(10):87. doi:10.1007/s11864-021-00886-5
   PubMed Web of Science ®Google Scholar
• Marron TU, Schwartz M, Corbett V, Merad M. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2022;9:571–581.
   PubMed Web of Science ®Google Scholar
• Wolmarans A, Lee B, Spyracopoulos L, LaPointe P. The mechanism of Hsp90 ATPase Stimulation by Aha1. Sci Rep. 2016;6(33179). doi:10.1038/srep33179
   PubMedGoogle Scholar
• Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell. 2002;10(6):1307–1318. doi:10.1016/S1097-2765(02)00785-2
   PubMed Web of Science ®Google Scholar
• Gu C, Wang Y, Zhang L, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):11. doi:10.1186/s13046-021-02220-1
   PubMed Web of Science ®Google Scholar
• Shi W, Qi L, You XB, et al. Identification of AHSA1 as a potential therapeutic target for breast cancer: bioinformatics analysis and in vitro studies. Curr Cancer Drug Targets. 2022;22(2):142–152. doi:10.2174/1568009622666220114151058
   PubMed Web of Science ®Google Scholar
• Cao R, Shao J, Hu Y, et al. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018;18(49). doi:10.1186/s12935-018-0551-x
   Google Scholar
• Zhang XR, Shao JL, Li H, Wang L. Silencing of LINC00707 suppresses cell proliferation, migration, and invasion of osteosarcoma cells by modulating miR-338-3p/AHSA1 axis. Open Life Sci. 2021;16(1):728–736. doi:10.1515/biol-2021-0070
   PubMed Web of Science ®Google Scholar
• Li W, Liu J. The prognostic and immunotherapeutic significance of AHSA1 in pan-cancer, and its relationship with the proliferation and metastasis of hepatocellular carcinoma. Front Immunol. 2022;13:845585.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang X, Gao Y, et al. RN181 is a tumor suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway. J Pathol. 2019;248(2):204–216. doi:10.1002/path.5246
   PubMed Web of Science ®Google Scholar
• Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2008;68(4):1188–1197. doi:10.1158/0008-5472.CAN-07-3268
   PubMed Web of Science ®Google Scholar
• Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345–360. doi:10.1038/nrm.2017.20
   PubMed Web of Science ®Google Scholar
• Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19(9):2560. doi:10.3390/ijms19092560
   PubMed Web of Science ®Google Scholar
• Prodromou C. Mechanisms of Hsp90 regulation. Biochem J. 2016;473(16):2439–2452. doi:10.1042/BCJ20160005
   PubMedGoogle Scholar
• Retzlaff M, Hagn F, Mitschke L, et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell. 2010;37(3):344–354. doi:10.1016/j.molcel.2010.01.006
   PubMed Web of Science ®Google Scholar
• Shao J, Wang L, Zhong C, Qi R, Li Y. AHSA1 regulates proliferation, apoptosis, migration, and invasion of osteosarcoma. Biomed Pharmacother. 2016;77:45–51. doi:10.1016/j.biopha.2015.11.008
   PubMed Web of Science ®Google Scholar
• Massagué J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306. doi:10.1038/nature03094
   PubMed Web of Science ®Google Scholar
• Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs. 2014;23(3):295–304. doi:10.1517/13543784.2014.867017
   PubMed Web of Science ®Google Scholar
• Nebenfuehr S, Kollmann K, Sexl V. The role of CDK6 in cancer. Int J Cancer. 2020;147(11):2988–2995. doi:10.1002/ijc.33054
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976. doi:10.1016/j.cell.2017.02.004
   PubMed Web of Science ®Google Scholar
• Miricescu D, Totan A, Stanescu S II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22(1):173. doi:10.3390/ijms22010173
   PubMed Web of Science ®Google Scholar
• Yan S, Liu H, Liu Z, et al. CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in myeloma bone disease. Cancer Med. 2020;9(2):737–744. doi:10.1002/cam4.2608
   PubMed Web of Science ®Google Scholar
• Xi J, Sun Y, Zhang M, et al. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway. Exp Cell Res. 2019;381(1):1–9. doi:10.1016/j.yexcr.2019.04.005
   PubMed Web of Science ®Google Scholar
• Cui Y, Bai Y, Yang J, et al. SIRT4 is the molecular switch mediating cellular proliferation in colorectal cancer through GLS mediated activation of AKT/GSK3β/CyclinD1 pathway. Carcinogenesis. 2021;42(3):481–492. doi:10.1093/carcin/bgaa134
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012
   PubMed Web of Science ®Google Scholar
• Uko NE, F GO, Matesic DF, Bowen JP. Akt Pathway Inhibitors. Curr Top Med Chem. 2020;20(10):883–900. doi:10.2174/1568026620666200224101808
   PubMed Web of Science ®Google Scholar
• Haque S, Morris JC. Transforming growth factor-β: a therapeutic target for cancer. Hum Vaccin Immunother. 2017;13(8):1741–1750. doi:10.1080/21645515.2017.1327107
   PubMed Web of Science ®Google Scholar
• Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci. 2002;115(Pt 15):3193–3206. doi:10.1242/jcs.115.15.3193
   PubMed Web of Science ®Google Scholar
• Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol. 2001;3(4):400–408. doi:10.1038/35070086
   PubMed Web of Science ®Google Scholar